drugset / Trial / NCT06011343
Tofacitinib Associated With Meglumine Antimoniate in Cutaneous Leishmaniasis
Phase 2/3
Unknown
22 enrolled
Hospital Universitário Professor Edgard Santos
Instituto Gonçalo Muniz FIOCRUZ BA · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
Phase 2/3 randomized and controlled clinical trial, which will evaluate the effectiveness of the association meglumine antimoniate (Glucantime) with tofacitinib in the cure of CL and the capacity of this association to reduce the time of cure of the disease.
Timeline
- Start
- 2023-10-01
- Primary completion
- 2024-10-01
- Completion
- 2025-07-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Meglumine antimonate | Other / unclassified | 20 mg/kg | Intravenous |
| Subject | Tofacitinib | Small molecule | 10 mg | Oral |